What are RBC-transfusion-dependence and -independence?-Reference-Cited by-同舟云学术

What are RBC-transfusion-dependence and -independence?

Published:2011-01 Issue:1 Volume:35 Page:8-11
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Gale R.P.,Barosi G.,Barbui T.,Cervantes F.,Dohner K.,Dupriez B.,Gupta V.,Harrison C.,Hoffman R.,Kiladjian J.-J.,Mesa R.,Mc Mullin M.F.,Passamonti F.,Ribrag V.,Roboz G.,Saglio G.,Vannucchi A.,Verstovsek S.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference29 articles.

1. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome;Jadersten;J Clin Oncol,2008

2. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience;Park;Blood,2008

3. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin+granulocyte colony-stimulating factor: significant effects on quality of life;Hellstrom-Lindberg;Br J Haematol,2003

4. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease;Palmer;Ann Intern Med,2010

5. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology 2007 clinical practice guideline update;Rizzo;J Clin Oncol,2008

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor Therapy;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis;Blood Advances;2024-08-28

3. Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2;Advances in Therapy;2024-07-11

4. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN);Annals of Hematology;2024-07-05